Our research in hematology
With ww5 delivering many firsts in hematology, we are committed to the next wave of advancements for patients through our extensive portfolio and rich hematology pipeline, spanning multiple modalities, combinations and differentiated research platforms including cell therapy and targeted protein degradation.
Featured in hematology
Intended for healthcare professionals, scientific audiences and media.
Leveraging multiple treatment modalities and advanced science, we seek to address hematologic conditions in many ways. We are harnessing key biologic processes that enable us to tap into targets previously considered undruggable and design new ways to affect pathways critical to the development and persistence of blood diseases.
We have the most robust portfolio of treatments for patients with multiple myeloma and continue our efforts to redefine the treatment paradigm. In leukemia, lymphoma and non-malignant hematologic disease, we deploy our expertise to discover, develop and deliver a robust portfolio that continues to bring innovative treatment options to patients in need.
Explore our stories
Our hematology focus areas
Leukemia
A group of blood cancers that develop in the lymphatic system.
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by early relapses and poor survival rates. Bristol Myers Squibb has played an important role in the development therapies for critical unmet needs associated with the disease.
Scientific and disease-state resources
Explore our stories
